3649 results for «480»

Filter By

3649 results

Mitral and tricuspid intervention

17 Feb 2024 – From PCR Tokyo Valves 2024

Consult this session to discover selected clinical cases regarding complex mitral and tricuspid interventions. Gain insights into phenotypes of secondary tricuspid regurgitation in echocardiography, learn about treatment effectiveness and one-year composite endpoint by clip size of TEER for AFMR, and more!

New possibilities in TEER

18 Feb 2024 – From PCR Tokyo Valves 2024

Watch this session to get an overview of a new TEER device, follow the step-by-step procedure related to initial experiences with this device for a Japanese patient with degenerative mitral regurgitation, learn about the latest data from RCT and registries, and follow discussions of challenging TEER...

New possibilities in

Rapid-fire - TAVI concomitant with CAD

17 Feb 2024 – From PCR Tokyo Valves 2024

In this series of rapid-fire case submissions, explore cases of TAVI concomitant with coronary artery disease. Learn about innovative procedures such as valve-in-valve chimney stenting, intermediate size THV implantation with coronary protection by chimney stenting, and more!

Rapid-fire - Bailout in SHD

17 Feb 2024 – From PCR Tokyo Valves 2024

Gain valuable insights into the bailout techniques in structural heart disease intervention in this session of rapid-fire submission cases (in Japanese).

Three-year results of HOST-POLYTECH-ACS RCT comparing durable- vs. degradable-polymer DES

30 Aug 2023

Alex Sticchi provides his take on the 3-year results of HOST-POLYTECH-ACS RCT which were presented by Hyo-Soo Kim during the ESC 2023 congress in Amsterdam.

Alessandro Sticchi

Author

Alessandro Sticchi
Three-year results of HOST-POLYTECH-ACS RCT comparing durable- vs. degradable-polymer DES

Management of mitral regurgitation patients undergoing TMVI screening

13 Jan 2022

This study's results emphasise the strengths and limitations of transcatheter mitral valve implantation (TMVI) as a novel and promising therapy providing predictable elimination of MR in most patients, by S. Ludwig et al.

Management of mitral regurgitation patients undergoing TMVI screening

Primary Outcomes of a Pivotal Multicenter Randomized Trial Comparing the AGENT Paclitaxel-Coated Ballon with Conventional Ballon Angioplasty for In-Stent Restenosis (AGENT IDE)

27 Oct 2023

Mirvat Alasnag provides her take on the AGENT IDE trial which was presented by Robert W. Yeh at TCT Congress 2023. This pivotal randomized trial compares the safety and efficacy of the AGENT DCB to conventional balloon angioplasty in patients with ISR. It is the first...

Dr. Mirvat Alasnag

Author

Mirvat Alasnag
Primary Outcomes of a Pivotal Multicenter Randomized Trial Comparing the AGENT Paclitaxel-Coated Ballon with Conventional Ballon Angioplasty for In-Stent Restenosis (AGENT IDE)

SIRONA completes enrollment! A leap in the DCB treatment of femoropopliteal arterial disease

02 Nov 2022

When transfemoral TAVI is not an option: rethinking alternative access strategies

18 Jun 2026

In this article, Ulrich Schäfer explores the evolving landscape of access strategies in transcatheter aortic valve implantation (TAVI). While the transfemoral approach remains the gold standard, a significant proportion of patients are not suitable due to peripheral vascular disease or anatomical constraints.
Drawing on clinical evidence and...

Author

Ulrich Schaefer
Alternative access, if transfemoral is not working
Didn’t find what you were looking for?